Anti-CD8α Antibody (OKT-8) 

Anti-CD8α Antibody (OKT-8) is an anti-human CD8α IgG2a monoclonal antibody. Anti-CD8α Antibody (OKT-8) can reduce the secretion of IFNγ. Anti-CD8α Antibody (OKT-8) can deplete CD8⁺ T cells. Anti-CD8α Antibody (OKT-8) can be used for researches on inflammation conditions and cancer such as B non-Hodgkin lymphomas (B-NHLs). The recommend isotype control of Anti-CD8α Antibody (OKT-8): Mouse IgG2a kappa, Isotype Control (HY-P99978)^[1][2].

Mouse IgG2a kappa

Mouse IgG2a kappa, Isotype Control

Human

CD8α

Anti-CD8α Antibody (OKT-8) (10 μg/mL，18-24 小时) 可显著阻断 CD4⁺ TEG011_CD8α 细胞分泌 IFNγ^[1]。
Anti-CD8α Antibody (OKT-8) (18-24 小时) 显著抑制 TEG011_CD8α 细胞的肿瘤反应性^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Anti-CD8α Antibody (OKT-8) (100-200 μg，腹腔注射，每周两次，持续 4 周) 可以耗竭患有 B 非霍奇金淋巴瘤 (B-NHLs) 异种移植物模型的 NSG 小鼠的 CD8⁺ T 细胞^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

925  [NCBI]

P01732

ELISA, FACS, Functional assay, Research in vivo

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

150 kDa

液体

Colorless to light yellow

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Immobilized CD8 alpha Protein, Human (HEK293, His, HY-P71662) can bind Anti-CD8α Antibody (OKT-8). The EC₅₀ for this effect is 13.50 ng/mL.

• [1]. Johanna I, et al. Adding Help to an HLA-A*24:02 Tumor-Reactive γδTCR Increases Tumor Control. Front Immunol. 2021 Oct 25;12:752699.  [Content Brief]

  [2]. Daneels W, et al. High efficacy of huCD20-targeted AcTaferon in humanized patient derived xenograft models of aggressive B cell lymphoma. Exp Hematol Oncol. 2024 Jun 3;13(1):59.  [Content Brief]